[go: up one dir, main page]

MA34767B1 - Compositions et procédés pour la modulation de fxr - Google Patents

Compositions et procédés pour la modulation de fxr

Info

Publication number
MA34767B1
MA34767B1 MA36062A MA36062A MA34767B1 MA 34767 B1 MA34767 B1 MA 34767B1 MA 36062 A MA36062 A MA 36062A MA 36062 A MA36062 A MA 36062A MA 34767 B1 MA34767 B1 MA 34767B1
Authority
MA
Morocco
Prior art keywords
compositions
methods
fxr modulation
fxr
present
Prior art date
Application number
MA36062A
Other languages
English (en)
Inventor
David C Tully
Paul Vincent Rucker
Phillip B Alper
Daniel Mutnick
Donatella Chianelli
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of MA34767B1 publication Critical patent/MA34767B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)

Abstract

La présente invention concerne des composés de Formule (I), un stéréoisomère, énantiomère, sel pharmaceutiquement acceptable ou son conjugué acide aminé ; les variables étant telles que définies présentement ; et leurs compositions pharmaceutiques qui sont utiles comme modulateurs de l'activité de récepteurs du Farnésoïde X (FXR).
MA36062A 2010-12-20 2013-06-28 Compositions et procédés pour la modulation de fxr MA34767B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061425189P 2010-12-20 2010-12-20
US201161554297P 2011-11-01 2011-11-01
PCT/US2011/062724 WO2012087519A1 (fr) 2010-12-20 2011-11-30 Compositions et procédés pour la modulation de fxr

Publications (1)

Publication Number Publication Date
MA34767B1 true MA34767B1 (fr) 2013-12-03

Family

ID=45349296

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36062A MA34767B1 (fr) 2010-12-20 2013-06-28 Compositions et procédés pour la modulation de fxr

Country Status (39)

Country Link
US (2) US9150568B2 (fr)
EP (1) EP2655370B1 (fr)
JP (1) JP5740483B2 (fr)
KR (1) KR101626046B1 (fr)
CN (1) CN103443099B (fr)
AP (1) AP3414A (fr)
AR (1) AR084425A1 (fr)
AU (1) AU2011345233B2 (fr)
BR (1) BR112013015452B1 (fr)
CA (1) CA2819825C (fr)
CL (1) CL2013001677A1 (fr)
CO (1) CO6801729A2 (fr)
CR (1) CR20130307A (fr)
CU (1) CU24152B1 (fr)
CY (1) CY1119530T1 (fr)
DK (1) DK2655370T3 (fr)
EA (1) EA025569B1 (fr)
ES (1) ES2645728T3 (fr)
GT (1) GT201300159A (fr)
HR (1) HRP20171615T1 (fr)
HU (1) HUE034150T2 (fr)
IL (1) IL226853A (fr)
JO (1) JO3297B1 (fr)
LT (1) LT2655370T (fr)
MA (1) MA34767B1 (fr)
MX (1) MX338845B (fr)
MY (1) MY163216A (fr)
NZ (1) NZ613234A (fr)
PE (1) PE20140207A1 (fr)
PH (1) PH12013501256A1 (fr)
PL (1) PL2655370T3 (fr)
PT (1) PT2655370T (fr)
RS (1) RS56335B1 (fr)
SG (1) SG191046A1 (fr)
SI (1) SI2655370T1 (fr)
TW (1) TWI427078B (fr)
UY (1) UY33815A (fr)
WO (1) WO2012087519A1 (fr)
ZA (1) ZA201304044B (fr)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014500318A (ja) * 2010-12-20 2014-01-09 アイアールエム・リミテッド・ライアビリティ・カンパニー ファルネソイドｘ受容体を調節するための組成物および方法
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
EP2545964A1 (fr) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Nouveaux composés se liant au fxr (nr1 h4) et modulant son activité
AU2013266398A1 (en) 2012-05-22 2015-01-22 Genentech, Inc. N-substituted benzamides and their use in the treatment of pain
CN103007081B (zh) * 2012-11-27 2013-12-04 鞠法红 一种治疗非酒精性脂肪肝的中药组合物
WO2014138692A1 (fr) 2013-03-07 2014-09-12 Califia Bio, Inc. Inhibiteurs de kinases de lignée mixte et procédés thérapeutiques
TN2016000143A1 (en) * 2013-11-05 2017-10-06 Novartis Ag Compositions and methods for modulating farnesoid x receptors.
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
EP3034499A1 (fr) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Nouveaux composés de modulation (FXR NR1H4)
EP3034501A1 (fr) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy contenant des composés de modulation (FXR NR1H4)
RU2017125365A (ru) * 2014-12-18 2019-01-21 Новартис Аг Производные азабициклооктана в качестве агонистов fxr для применения при лечении заболеваний печени и желудочно-кишечных заболеваний
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
JP6785788B2 (ja) 2015-03-31 2020-11-18 エナンタ ファーマシューティカルズ インコーポレイテッド Ｆｘｒ／ｔｇｒ５アゴニストとしての胆汁酸誘導体およびその使用方法
CN106146483A (zh) * 2015-04-23 2016-11-23 上海迪诺医药科技有限公司 杂环类法尼酯衍生物x受体调节剂
CN106946867B (zh) * 2016-01-06 2019-11-12 广州市恒诺康医药科技有限公司 Fxr受体调节剂及其制备方法和用途
WO2017133521A1 (fr) * 2016-02-01 2017-08-10 山东轩竹医药科技有限公司 Agoniste du récepteur fxr
CA3012583A1 (fr) * 2016-02-08 2017-08-17 Redx Pharma Plc Composes heterocycliques, en particulier derives de 2-oxo -4,4,5,5,6,6,7,7-octahydrobenzoxazole, et leur utilisation en tant que composes antibacteriens
EP3419625B1 (fr) * 2016-02-22 2021-04-07 Novartis AG Méthodes d'utilisation d'agonistes de fxr
US11110083B2 (en) * 2016-02-22 2021-09-07 Novartis Ag Methods for treating liver disorders using FXR agonists
HK1257648A1 (zh) 2016-02-22 2019-10-25 Novartis Ag Fxr促效剂之使用方法
WO2017189652A1 (fr) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Dérivés d'isoxazole utilisés comme agonistes de fxr et leurs procédés d'utilisation
US10080742B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017189663A1 (fr) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Dérivés d'isoxazole utilisés comme agonistes de fxr et leurs méthodes d'utilisation
US10138228B2 (en) 2016-05-18 2018-11-27 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use therof
WO2017201155A1 (fr) * 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Dérivés d'isoxazole utilisés comme agonistes de fxr et leurs méthodes d'utilisation
WO2017201150A1 (fr) * 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Analogues de l'isoxazole comme agonistes de fxr et leurs procédés d'utilisation
CA2968836C (fr) 2016-06-13 2025-09-02 Gilead Sciences, Inc. Composes modulant fxr (nr1h4)
AR108711A1 (es) * 2016-06-13 2018-09-19 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4)
JP6678779B2 (ja) 2016-06-13 2020-04-08 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒ（ｎｒ１ｈ４）調節化合物
TW201808283A (zh) 2016-08-05 2018-03-16 廣東東陽光藥業有限公司 含氮三環化合物及其在藥物中的應用
JP7093341B2 (ja) 2016-08-23 2022-06-29 アルデリックス， インコーポレイテッド 代謝異常状態及び代謝障害を治療するためのホルモン受容体調節薬
WO2018039384A1 (fr) * 2016-08-23 2018-03-01 Ardelyx, Inc. Composés d'isoxazolyl-carbonyloxy azabicyclo [3.2.1] octane en tant qu'activateurs de fxr
CN108495850B (zh) 2016-08-31 2021-11-26 江苏恒瑞医药股份有限公司 氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用
JOP20190040A1 (ar) * 2016-09-14 2019-03-10 Novartis Ag توليفة من ناهضات fxr
CA3036757A1 (fr) * 2016-09-14 2018-03-22 Novartis Ag Nouveaux regimes d'agonistes de fxr
CN108430998B (zh) * 2016-09-28 2021-07-09 四川科伦博泰生物医药股份有限公司 氮杂双环衍生物及其制备方法和用途
CN109906223A (zh) * 2016-10-04 2019-06-18 英安塔制药有限公司 异噁唑类似物作为fxr激动剂及其使用方法
US10597391B2 (en) 2016-10-26 2020-03-24 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof
CN108017636A (zh) * 2016-11-04 2018-05-11 合帕吉恩治疗公司 作为fxr调节剂的含氮杂环化合物
WO2018153933A1 (fr) 2017-02-21 2018-08-30 Genfit Combinaison d'un agoniste ppar avec un agoniste fxr
EP4122464B1 (fr) 2017-03-28 2024-05-15 Gilead Sciences, Inc. Combinaisons thérapeutiques pour le traitement des maladies du foie
HRP20220026T1 (hr) 2017-04-12 2022-04-01 Il Dong Pharmaceutical Co., Ltd. Derivati izoksazola kao agonisti nuklearnog receptora i njihove uporabe
WO2018190643A1 (fr) * 2017-04-12 2018-10-18 Il Dong Pharmaceutical Co., Ltd. Dérivés d'isoxazole en tant qu'agonistes du récepteur nucléaire et leur utilisation
CN109265471B (zh) * 2017-06-30 2021-06-04 轩竹生物科技有限公司 Fxr受体激动剂
CA3068928C (fr) * 2017-07-06 2022-05-31 Xuanzhu (Hainan) Biopharmaceutical Co., Ltd. Agoniste fxr
CN109320517B (zh) * 2017-07-31 2021-08-17 轩竹生物科技有限公司 Fxr受体激动剂
AR114930A1 (es) * 2017-09-12 2020-11-11 Novartis Ag Composición farmacéutica
WO2019055808A1 (fr) * 2017-09-14 2019-03-21 Ardelyx, Inc. Modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques mutagènes et fibrotiques
AU2018360577A1 (en) * 2017-11-01 2020-06-18 Bristol-Myers Squibb Company Bridged bicyclic compounds as farnesoid X receptor modulators
WO2019089664A1 (fr) 2017-11-01 2019-05-09 Bristol-Myers Squibb Company Composés multicycliques en tant que modulateurs du récepteur farnésoïde x
WO2019089670A1 (fr) * 2017-11-01 2019-05-09 Bristol-Myers Squibb Company Composés d'alcène utilisés en tant que modulateurs du récepteur farnésoïde x
BR112020008157A2 (pt) * 2017-11-01 2020-10-06 Bristol-Myers Squibb Company compostos espirocíclicos como moduladores do receptor farnesoide x
EP3704112B1 (fr) 2017-11-01 2023-09-27 Bristol-Myers Squibb Company Composés alkène-spirocycliques en tant que modulateurs du récepteur de farnésoïde x
TW201936189A (zh) * 2017-11-30 2019-09-16 瑞士商諾華公司 用於使用fxr激動劑之方法
WO2019118571A1 (fr) 2017-12-12 2019-06-20 Enanta Pharmaceuticals, Inc. Analogues de l'isoxazole utilisés en tant qu'agonistes de fxr et leurs procédés d'utilisation
WO2019120088A1 (fr) 2017-12-22 2019-06-27 四川科伦博泰生物医药股份有限公司 Dérivé d'isoxazole, son procédé de préparation et son utilisation
CN110128432B (zh) 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
US10829486B2 (en) 2018-02-14 2020-11-10 Enanta Pharmacueticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US11787828B2 (en) 2018-03-22 2023-10-17 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
CN110357875B (zh) * 2018-04-10 2022-06-21 浙江海正药业股份有限公司 氮杂双环辛烷类衍生物、其制备方法及其在医药上的用途
KR20210015849A (ko) 2018-05-31 2021-02-10 노파르티스 아게 트로피펙소르 및 세니크리비록을 포함하는 조합물
CA3045644C (fr) 2018-06-13 2024-01-16 Pfizer Inc. Antagonistes du recepteur glp-1 et leurs utilisations
WO2020001304A1 (fr) * 2018-06-26 2020-01-02 轩竹（海南）医药科技有限公司 Agoniste du récepteur fxr
WO2020011146A1 (fr) * 2018-07-11 2020-01-16 中国医药研究开发中心有限公司 Composés 1,2,4-oxadiazole, leur procédé de préparation et utilisation médicale associée
AU2019309727B2 (en) 2018-07-25 2021-12-23 Novartis Ag NLRP3 inflammasome inhibitors
EP3981467A1 (fr) * 2018-08-08 2022-04-13 Inorbit Therapeutics Ab Composés utiles dans la modulation du récepteur farnésoïde x et leurs procédés de fabrication et d'utilisation
US11254660B2 (en) 2018-08-31 2022-02-22 Pfizer Inc. Combinations for treatment of NASH/NAFLD and related diseases
WO2020117962A1 (fr) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions pour le traitement de la fibrose et de l'inflammation
EP3911647B1 (fr) 2019-01-15 2023-12-13 Gilead Sciences, Inc. Composé d'isoxazole comme agoniste de fxr et les compositions pharmaceutiques le comprenant.
WO2020156241A1 (fr) 2019-01-31 2020-08-06 中国医药研究开发中心有限公司 Composés cycliques aromatiques ou cycliques hétéroaromatiques, procédé de préparation correspondant et utilisation médicale associée
CN113727973B (zh) 2019-02-15 2025-08-29 百时美施贵宝公司 可用作类法尼醇x受体调节剂的取代酰胺化合物
AR118050A1 (es) 2019-02-15 2021-09-15 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
AU2020221371A1 (en) 2019-02-15 2021-10-07 Bristol-Myers Squibb Company Substituted amide compounds useful as farnesoid x receptor modulators
CN113677666A (zh) 2019-02-15 2021-11-19 百时美施贵宝公司 作为类法尼醇x受体调节剂的经取代的双环化合物
AU2020225225B2 (en) 2019-02-19 2022-12-22 Gilead Sciences, Inc. Solid forms of FXR agonists
JP2022524820A (ja) * 2019-03-13 2022-05-10 ノバルティス アーゲー 医薬組成物
CN111825667B (zh) * 2019-04-19 2023-07-25 中国科学院上海药物研究所 Fxr小分子激动剂及其制备方法和用途
KR20250076664A (ko) 2019-04-19 2025-05-29 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 Fxr 소분자 작용제 및 이의 제조 방법과 용도
CN111825701B (zh) * 2019-04-19 2023-12-08 正大天晴药业集团股份有限公司 含苯并噻唑的三环类fxr调节剂化合物
WO2020231917A1 (fr) 2019-05-13 2020-11-19 Enanta Pharmaceuticals, Inc. Dérivés d'isoxazole utilisés en tant qu'agonistes de fxr et leurs procédés d'utilisation
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
EP3972596B1 (fr) * 2019-05-20 2025-07-16 Pfizer Inc. Combinaisons comprenant du benzodioxol en tant qu'agonistes de glp-1r destinées à être utilisées dans le traitement de la nash/nafld et de maladies associées
US20220241376A1 (en) 2019-07-18 2022-08-04 Enyo Pharma Method for decreasing adverse-effects of interferon
AU2020316740A1 (en) 2019-07-23 2022-01-27 Novartis Ag Treatment comprising FXR agonists
TW202114672A (zh) 2019-07-23 2021-04-16 瑞士商諾華公司 使用fxr促效劑的肝臟疾病之組合治療
WO2021044351A1 (fr) 2019-09-06 2021-03-11 Novartis Ag Procédés de traitement d'une maladie hépatique à l'aide d'inhibiteurs de lta4h
JP2022548617A (ja) 2019-09-19 2022-11-21 ノバルティス アーゲー Ｆｘｒアゴニストを含む処置
JP2022550312A (ja) 2019-09-30 2022-12-01 ノバルティス アーゲー Ｆｘｒアゴニストの使用を含む処置
CN114728954B (zh) * 2019-11-29 2023-10-17 广东东阳光药业股份有限公司 Tropifexor的新晶型及其制备方法
CN114728955A (zh) * 2019-11-29 2022-07-08 广东东阳光药业有限公司 Tropifexor的新晶型及其制备方法
WO2021108974A1 (fr) 2019-12-03 2021-06-10 Gannex Pharma Co., Ltd Composés pour moduler l'activité du fxr et leurs utilisations
AU2020402177A1 (en) 2019-12-10 2022-06-16 Pfizer Inc. Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo(d) (1,3)dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo(d) imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt
CN114929219A (zh) 2019-12-20 2022-08-19 诺华股份有限公司 使用整联蛋白抑制剂组合治疗肝脏疾病
WO2021133948A1 (fr) 2019-12-23 2021-07-01 Axcella Health Inc. Compositions et méthodes pour le traitement de maladies et de troubles hépatiques
CN114945361A (zh) 2020-01-15 2022-08-26 法国国家卫生及研究医学协会 Fxr激动剂在治疗丁型肝炎病毒感染中的用途
BR112022017578A2 (pt) 2020-03-27 2022-10-18 Pfizer Tratamento do diabetes tipo 2 ou obesidade ou sobrepeso com ácido 2-[(4-{6-[(4-ciano-2-fluorobenzil)óxi]piridin-2-il}piperidin-1-il)metil]-1-[(2s)-oxetan-2-ilmetil]-1h-benzimidazol-6-carboxílico ou um sal farmacêutico do mesmo
WO2021233461A1 (fr) * 2020-05-22 2021-11-25 苏州晶云药物科技股份有限公司 Nouvelle forme cristalline d'un composé benzothiazole et son procédé de préparation
EP4161925A4 (fr) * 2020-06-09 2024-09-04 Viking Therapeutics, Inc. Compositions et méthodes de traitement de troubles hépatiques
IL301285A (en) 2020-09-10 2023-05-01 Precirix N V A portion of an antibody against FAP
CN114315830B (zh) * 2020-09-30 2025-08-12 中国科学院上海药物研究所 Fxr小分子激动剂及其制备方法和用途
US20240100125A1 (en) 2021-01-14 2024-03-28 Enyo Pharma Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
CN113024552B (zh) * 2021-03-26 2022-08-05 厦门市博瑞来医药科技有限公司 一类新型非甾体fxr激动剂的合成及其应用
EP4329761A1 (fr) 2021-04-28 2024-03-06 ENYO Pharma Potentialisation forte d'effets d'agonistes de tlr3 à l'aide d'agonistes de fxr en tant que traitement combiné
CN113292555B (zh) * 2021-04-28 2022-03-18 武汉纽瑞斯医药科技有限公司 一种Tropifexor的制备方法
MX2024002613A (es) 2021-08-31 2024-03-22 Pfizer Formas solidas de acido 2-[(4-{6-[(4-ciano-2-fluorobencil)oxi]piri din-2-il}piperidin-1-il)metil]-1-[(2s)-oxetan-2-ilmetil]-1h-benci midazol-6-carboxilico, sal de 1,3-dihidroxi-2-(hidroximetil)propan -2-amina.
US12443426B2 (en) 2021-12-07 2025-10-14 Nutanix, Inc. Techniques for switching device implementations for virtual devices
ES3029434T3 (en) * 2022-03-16 2025-06-24 Cascade Pharmaceuticals Inc A fxr small molecule agonist, the preparation and use thereof
WO2023203135A1 (fr) 2022-04-22 2023-10-26 Precirix N.V. Anticorps radiomarqué amélioré
WO2023213801A1 (fr) 2022-05-02 2023-11-09 Precirix N.V. Pré-ciblage
WO2023228023A1 (fr) 2022-05-23 2023-11-30 Pfizer Inc. Traitement du diabète de type 2 ou contrôle de la gestion du poids avec de l'acide 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-méthylbenzo[d][1,3]dioxol-4-yl)pipéridin-1-yl)méthyl)-1-(((s)-oxétan-2-yl)méthyl)-1h-benzo[d]imidazole-6-carboxylique ou un sel pharmaceutique de celui-ci
TW202408494A (zh) * 2022-06-30 2024-03-01 南韓商日東製藥股份有限公司 異噁唑衍生物及其鹽的新晶型以及包括其之醫藥組合物
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
EP4495125A1 (fr) * 2023-07-19 2025-01-22 Freie Universität Berlin Procédé de synthèse sans catalyseur pour introduire un fragment trifluorométhoxy dans au moins un composé organique
WO2025099561A1 (fr) 2023-11-07 2025-05-15 Pfizer Inc. Formulations de matrice à libération contrôlée orales d'acide 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}pipéridin-1-yl)méthyl]-1-[(2s)-oxétan-2-ylméthyl]-1h-benzimidazole-6-carboxylique ou d'un sel pharmaceutiquement acceptable de celui-ci
WO2025224648A1 (fr) 2024-04-26 2025-10-30 Pfizer Inc. Compositions/formulations orales de l'acide 2-({4-[(2s)-2-(4-chloro-2-fluorophényl)-2-méthyl-1,3-benzodioxol-4-yl]pipéridin-1-yl}méthyl)-1-[(2s)-oxétan-2-ylméthyl]-1h-benzimidazole-6-carboxylique ou d'un sel pharmaceutiquement acceptable de celui-ci

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
JPH0672123B2 (ja) 1986-08-21 1994-09-14 セントラル硝子株式会社 トリフルオロメチル基を有するシクロヘキサンカルボン酸の製造方法
US7319109B2 (en) 2002-11-22 2008-01-15 Smith Kline Beecham Corporation Farnesoid X receptor agonists
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
AU2006311422A1 (en) 2005-11-09 2007-05-18 Memory Pharmaceuticals Corporation 1 h-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof
BRPI0619126A2 (pt) 2005-12-02 2011-09-13 Pfizer Ltd derivados espirocìclicos, composição farmacêutica e usos dos mesmos
US7863302B2 (en) * 2006-02-03 2011-01-04 Eli Lilly And Company Compounds and methods for modulating FX-receptors
JP2007230909A (ja) * 2006-03-01 2007-09-13 Univ Of Tokyo 置換イソキサゾール誘導体
AR061101A1 (es) 2006-05-24 2008-08-06 Lilly Co Eli Compuesto de fenil-triazolil- metoxi- arilo, su uso para la manufactura de un medicamento y composicion farmaceutica que lo comprende
EP1894924A1 (fr) * 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Composés hétérocycliques de liason du FXR
KR20100044810A (ko) * 2007-07-02 2010-04-30 글락소스미스클라인 엘엘씨 파네소이드 ｘ 수용체 효능제
TW200906823A (en) * 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
MX2010004450A (es) 2007-10-22 2010-05-05 Schering Corp Derivados heterociclo biciclicos y su uso como moduladores de la actividad de gpr119.
EP2289883A1 (fr) * 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Nouveaux composés modulant l'activité du recepteur FXR (NR1H4)
WO2011053688A1 (fr) 2009-10-29 2011-05-05 Schering Corporation Dérivés de pipéridine bicycliques pontés et leurs procédés d'utilisation
US20140039007A1 (en) 2010-12-20 2014-02-06 David C. Tully Compositions and methods for modulating farnesoid x receptors
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
JP2014500318A (ja) 2010-12-20 2014-01-09 アイアールエム・リミテッド・ライアビリティ・カンパニー ファルネソイドｘ受容体を調節するための組成物および方法

Also Published As

Publication number Publication date
CA2819825A1 (fr) 2012-06-28
CY1119530T1 (el) 2018-03-07
SG191046A1 (en) 2013-07-31
UY33815A (es) 2012-07-31
US20130331349A1 (en) 2013-12-12
AP2013006926A0 (en) 2013-06-30
HUE034150T2 (en) 2018-01-29
NZ613234A (en) 2015-01-30
BR112013015452A2 (pt) 2016-09-20
IL226853A (en) 2015-11-30
ZA201304044B (en) 2014-02-26
PH12013501256A1 (en) 2016-07-29
JP5740483B2 (ja) 2015-06-24
PL2655370T3 (pl) 2018-01-31
US9150568B2 (en) 2015-10-06
AU2011345233B2 (en) 2015-11-12
CL2013001677A1 (es) 2013-12-27
KR20130109210A (ko) 2013-10-07
LT2655370T (lt) 2017-10-25
EP2655370A1 (fr) 2013-10-30
CR20130307A (es) 2013-08-07
MY163216A (en) 2017-08-30
RS56335B1 (sr) 2017-12-29
CA2819825C (fr) 2019-05-07
PT2655370T (pt) 2017-11-14
PE20140207A1 (es) 2014-02-23
CU24152B1 (es) 2016-02-29
DK2655370T3 (da) 2017-11-06
JP2014500317A (ja) 2014-01-09
US20150366856A1 (en) 2015-12-24
TW201302739A (zh) 2013-01-16
MX338845B (es) 2016-05-03
EP2655370B1 (fr) 2017-08-02
HRP20171615T1 (hr) 2017-12-01
JO3297B1 (ar) 2018-09-16
AP3414A (en) 2015-09-30
MX2013007180A (es) 2014-01-23
CN103443099B (zh) 2016-03-23
CU20130082A7 (es) 2013-10-29
AR084425A1 (es) 2013-05-15
KR101626046B1 (ko) 2016-06-01
CN103443099A (zh) 2013-12-11
AU2011345233A1 (en) 2013-07-18
EA025569B1 (ru) 2017-01-30
EA201390934A1 (ru) 2013-11-29
SI2655370T1 (sl) 2017-12-29
TWI427078B (zh) 2014-02-21
ES2645728T3 (es) 2017-12-07
CO6801729A2 (es) 2013-11-29
BR112013015452B1 (pt) 2021-02-02
WO2012087519A1 (fr) 2012-06-28
GT201300159A (es) 2014-06-06

Similar Documents

Publication Publication Date Title
MA34767B1 (fr) Compositions et procédés pour la modulation de fxr
MA39088A1 (fr) Compositions et procédés pour moduler des récepteurs farnesoïde x
MA32729B1 (fr) Derives d&#39;acide 1-amino-2-cyclobutylethylboronique
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
EA200970612A1 (ru) Производные индола в качестве агонистов рецептора s1p1
MA32150B1 (fr) Inhibiteurs heterocycliques de la stearoyl-coa desaturase
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MA37519B1 (fr) Composés et compositions pour inhiber l&#39;activité d&#39;abl1, abl2 et bcr-abl1
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
MA35716B1 (fr) Formulations pharmaceutiques
TN2018000106A1 (en) Farnesoid x receptor modulators
EA200900048A1 (ru) Новые карбонилированные (аза)циклогексаны в качестве лигандов d3 рецептора дофамина
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
EA200870079A1 (ru) Замещенные имидазолы и их применение в качестве пестицидов
MA29839B1 (fr) Derives de carboxamides servant d&#39;antagonistes des recepteurs muscariniques
MA34094B1 (fr) Dérivés de 3-(hétéroarylamino)-1,2,3,4-tétrahydro-9h-carbazole et leur utilisation comme modulateurs du récepteur de la prostaglandine d2
MA35407B1 (fr) Modulateurs allostériques positifs des récepteurs nicotiniques d&#39;acétylcholine
EA200601895A1 (ru) 3-(4-гетероарилциклогексиламино)циклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
MA33693B1 (fr) Dérivés de pyrazole qui modulent la stéroyl-coa désaturase
MA32479B1 (fr) Compoés nouveaux actifs comme antagonistes des recepteurs muscariniques
MA31863B1 (fr) Dérivés de pyrazole comme inhibiteurs de 5-lo
MA38250B1 (fr) Nouveau dérivés d&#39;hydantoïne pour leurs utilisations dans le traitement de maladies, comme l&#39;osteoporose et la thrombocytopenie
MA41174B1 (fr) Dérivés d&#39;imidazopyridazine utilisés en tant qu&#39;inhibiteurs de pi3kbeta
TN2012000563A1 (fr) Nouvelle association entre le 4(3-(cis-hexahydrocyclopenta(c)pyrrol-2(1-h)-yl)propoxy)benzamide et un antagoniste des recepteurs nmda et les compositions pharmaceutiques qui la contiennent.